Aim To observe the clinical efficacy and the safty of ticagrelor in patients with clopidogrel resistance.Methods A total of 136 patients with clopidogrel resistance after coronary intervention in the Department of Cardiology from February 2014-December 2014 of our hospital were enrolled in this study, the subjects were divided into ticagrelor group and clopidogrel group according to a randomized controlled principle, 68 cases in each group. Patients with clopidogrel resistance received ticagrelor treatment （90 mg, twice daily） or clopidogrel treatment （150 mg daily）. After the treatment for 3 days patients with thromboelastography were reviewed, to evaluate platelet inhibition rate. Following up six months, observed major adverse cardiovascular events （MACE） and bleeding events were observed.Results After the treatment for 3 days, the inhition ratio against adenosine diphosphate （ADP） in patients with clopidogrel resistance in ticagrelor group was signifycantly higher than in the clopidogrel group, MA_ADP lower than clopidogrel group, the difference was statistically significant （P<0.05）. The incidence of adverse events in the two groups showed no significant difference （P>0.05）. There were no serious bleeding events and cardiovascular deaths during the follow-up. Clopidogrel group had 1 case of stent thrombosis, 1 case of nonfatal myocardial infarction.Conclusions Ticagrelor appliea in patients with clopidogrel resistance has rapid onset and good anti-platelet effect, little serious complications, and the same security effect as clopidogrel, it is worth in clinical practice.